explore -WSS

explore

author：hotspot 2025-09-27 10:00:56 - browse：24

A new asthma treatment that could be administered just once every six months has succeeded in two Phase 3 trials, developer GlaxoSmithKline announced Tuesday.

The drug, depemokimab, is designed to treat asthma by targeting a protein called interleukin-5, or IL-5. The protein is linked to the type of inflammation found in most severe asthma cases, according to the pharma company.

Depemokimab hit its primary endpoints in the trials, reducing asthma attacks over a year’s time frame. The company didn’t disclose exact details from the SWIFT-1 and SWIFT-2 trials.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： UCSF medical school apologizes for unethical prisoner experiments

WSS

Extreme heat events are a public health emergency

The new shift in health care is toward less care

The drug industry sees a key ally in the Senate prevail

White House calls on federal agencies to crack down on AI abuses

Diversify hospital leadership teams to protect BIPOC patient health

'Ancient DNA,' 23andMe reveal African American ancestries

focus

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

At least 13 dead in Texas as scorching temps continue

Medicare solvency divides Republicans at the presidential debate

Supreme Court strikes down use of affirmative action

The new shift in health care is toward less care

New air purifier tech could be key to improving indoor air quality

'Ancient DNA,' 23andMe reveal African American ancestries

Dobbs anniversary: the lost opportunity of abortion as health care

What the cancer research community can learn from the Covid response

DIEP, the 'gold standard' of breast reconstruction, is under threat

Medicare will require more price transparency from hospitals

focus

My superpower is killing ticks

Victims of gun violence feel impacts long after bullet wound

'Ancient DNA,' 23andMe reveal African American ancestries

More doctors should go into startup world

Dramatically reducing cancer deaths requires the PASTEUR Act

Microsoft strikes partnership with Duke Health to advance health AI

focus

entertainment

hotspot

hotspot